UI Hospitals and Clinics

Clinical Trial Details

Short Title
A Phase II Pilot Trial of Bortezomib (PS-341, VelcadeĀ®, IND# 58,443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)
Official Title

A Phase II Pilot Trial of Bortezomib (PS-341, Velcade®, IND# 58,443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)

Description

Participants in this study have been diagnosed with acute lymphoblastic leukemia (ALL) or a cancer of the immune system tissue. The purpose of this study is test effectiveness of adding a drug called bortezomib to the standard therapy for relapsed ALL. Approximately 6 people will take part in this study conducted by investigators at the University of Iowa. Study involvement will last approximately 15 weeks.

Start Date
June 23, 2009
End Date
June 23, 2019
Gender Preference
None
Age Group
0 - 99 years
Principal Investigator
Ayman El-Sheikh, MD
Contact Info

Victoria Scaccia, 319-356-7875

Department
Department or Field of Study
Keywords
acute lymphoblastic leukemia (ALL) ; bortezomib ; cancer ; el-sheikh ; immune system tissue ; IRB#200904794 ; pediatric ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.